SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Edward W. Richmond who wrote (770)11/24/1999 12:02:00 PM
From: Ian@SI  Read Replies (1) of 1321
 
Ed,

The biggest problem with Photofrin acceptance was that it was initially approved only for Palliative care of cancers for which there were other treatments.

Oncologists generally are untrained in Lasers; slow to adopt new technology; and their hospitals weren't anxious to buy equipment that noone was trained to use.

None of these conditions exist with Visudyne. There is no alternative that preserves vision. Retinal specialists have long been using lasers. And if the conference call comments posted by Julian yesterday are credible, we can expect that there will be significant usage of Visudyne to treat a wide variety of eye problems stemming from abnormal blood vessels, not just AMD.

I'd wondered why QLT already put in capacity to make more than 1M doses annually. They also indicated that they have the ability to rapidly increase that capacity. It seemed strange to me at the time. Now it seems that, just perhaps, they might have anticipated some off label usage???

Ian.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News